Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
150%(3 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_2
2
50%
Ph phase_3
1
25%
Ph phase_1
1
25%

Phase Distribution

1

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Terminated(1)
Other(1)

Detailed Status

Completed2
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (25.0%)
Phase 22 (50.0%)
Phase 31 (25.0%)

Trials by Status

unknown125%
completed250%
terminated125%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_2

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administration

NCT01095497
completedphase_2

CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12

NCT01095510
unknownphase_1

CINRYZE as a Donor Pre-treatment Strategy in Kidney Recipients of KDPI>60%

NCT02435732
terminatedphase_3

A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Participants With Kidney Transplant

NCT02547220

Clinical Trials (4)

Showing 4 of 4 trials
NCT01095497Phase 2

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administration

Completed
NCT01095510Phase 2

CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12

Completed
NCT02435732Phase 1

CINRYZE as a Donor Pre-treatment Strategy in Kidney Recipients of KDPI>60%

Unknown
NCT02547220Phase 3

A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Participants With Kidney Transplant

Terminated

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4